AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02975349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tecfidera
Description: Tecfidera; 120 mg hard capsule BID for 7 days then 240 mg hard capsule BID for duration of treatment (48 weeks).
Study NCT02975349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Following Placebo for 24 weeks, participants received Evobrutinib 25 milligram (mg) orally, once daily (QD) from Week 24 to 48 weeks.
Study NCT06484725 — intervention group
Intervention type: GENETIC
Intervention: Oncotype DX assay
Description: Oncotype DX assay (Genomic Health, Inc, Redwood City, Calif) is a 21 gene panel developed to predict the risk of tumor recurrence in patients with ER-positive and human epidermal growth factor 2 (HER2)- negative breast cancer (BC); nowadays, this test represents a standard of care to guide adjuvant chemotherapy decision recommended in several guidelines. According to Oncotype DX Recurrent Score (RS)® a high RS shows a worse prognosis and predicts chemotherapy benefit in patients with ER-positive HER2-negative BC.
Study NCT03849287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333, formula I
Description: Test drug
Study NCT03849287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333, formula II
Description: Test drug
Study NCT03849287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330, D090
Description: Reference Drug
Study NCT02085135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 5461
Description: Sublingual tablet taken once daily
Study NCT02891252 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: outpatient procedure
Study NCT04099836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg IV every 3 weeks
Study NCT04099836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg IV every 3 weeks
Study NCT04046276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Aerobic program
Description: Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
Study NCT04046276 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
Study NCT04046276 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Medium Intensity Aerobic program
Description: Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
Study NCT01339208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine diabetes intervention
Description: 3 month duration telemedicine consultation and diabetes education
Study NCT01465373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endometrin
Description: 100 mg per vagina TID
Study NCT01465373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone in Oil
Description: 50 mg IM injection daily
Study NCT04494477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The IN•clued program
Description: The INclued program as previously described.
Study NCT00806650 — intervention group
Intervention type: GENETIC
Intervention: gene expression analysis
Description: Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
Study NCT00806650 — intervention group
Intervention type: GENETIC
Intervention: protein expression analysis
Description: Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
Study NCT00806650 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: diagnostic laboratory biomarker analysis
Description: Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
Study NCT00806650 — intervention group
Intervention type: OTHER
Intervention: immunoenzyme technique
Description: Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
Study NCT00806650 — intervention group
Intervention type: OTHER
Intervention: immunohistochemistry staining method
Description: Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
Study NCT00744991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzastaurin
Description: 1125 milligrams (mg) loading dose then 500 mg, oral, daily, until disease progression
Study NCT03170908 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interpersonal Psychotherapy
Description: Interpersonal Psychotherapy (IPT) is an empirically-validated time-limited treatment for depression
Study NCT00570895 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Visit 1: Subjects will receive 1mg iron-58 sulfate as an aqueous solution with 50mg ascorbic acid.~Visit 2: Subjects will consume a meal of a bread muffin labelled with 4mg of iron-57 as ferrous fumarate, and a glass of apple juice containing 0 or 25mg ascorbic acid.~Visit 3: During this admission the apple juice will contain either 0 or 25mg ascorbic acid, the opposite of what was given to the subject in visit 2.
Study NCT04020965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sanitation
Description: Only households enrolled in the original WASH Benefits study and assigned to the combined WASH and combined WASH + nutrition arms received this intervention.~Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, and new or upgraded pit latrine for each household enrolled in the WASH Benefits Kenya study. Upgrades included structural improvements, plastic slabs, and superstructure improvements. Households in intervention villages not enrolled in the original trial did not receive any hardware.~Promotion: Local promoters visited compounds enrolled in the WASH Benefits Kenya study at least monthly during the first year and bi-monthly during the second (and last) year to deliver behavior change messages that focused on handwashing with soap at critical times around food preparation, defecation, and contact with feces. Compounds in intervention villages that were not enrolled in the original trial did not receive such visits.
Study NCT04020965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Handwashing
Description: Only households enrolled in the original WASH Benefits study and assigned to the combined WASH and combined WASH + nutrition arms received this intervention.~Hardware: Handwashing dual tippy tap stations, including jugs for clean and for soapy water, for each compound. Handwashing stations were stocked with soap for the duration of the WASH Benefits Kenya study. Compounds in intervention villages who were not enrolled in the WASH Benefits Kenya study did not receive any hardware.~Promotion: Local promoters visited compounds enrolled in the WASH Benefits Kenya study at least monthly during the first year and bi-monthly during the second (and last) year to deliver behavior change messages that focused on the use of latrines for defecation and the removal of human and animal feces from the compound. Compounds in intervention villages that were not enrolled in the WASH Benefits Kenya study did not receive such visits.
Study NCT04020965 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: Supplement: Lipid-based Nutrient Supplement (LNS) twice daily from ages 6 to 24 months, among children enrolled in the WASH Benefits Kenya study and for the duration of that study. Children in intervention villages who were not enrolled in the WASH Benefits Kenya study did not receive any supplements.~Promotion: Local promoters visited compounds enrolled in the WASH Benefits Kenya study at least monthly during the first year and bi-monthly during the second (and last) year to deliver the following behavior change messages: (1) practice exclusive breastfeeding from birth to 6 months of age; (2) continue breast feeding with the introduction of LNS; (3) provide your child micronutrient-rich foods and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old. Compounds in intervention villages that were not enrolled in the WASH Benefits Kenya study did not receive such visits.
Study NCT02767830 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Excercise and Nutrition Program
Study NCT04062474 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural Intervention with TNF-α inhibitor
Description: Epidural administration with TNF-α inhibitor
Study NCT02910674 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Dario Blood Glucose Monitoring System
Description: Accuracy with usability assessment
Study NCT01879865 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Non-stimulation
Description: The volunteers will be wearing noise-cancelling headphones (silent) and will be stimulated as little as possible. The volunteer will be instructed to keep his/her eyes closed.
Study NCT01879865 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stimulation
Description: The volunteers will be wearing noise-cancelling headphones, through which they will hear a continuous loop of recorded operating room noise (monitor beeps, talking), to simulate operating room conditions. The volunteer will be instructed to keep his/her eyes closed.
Study NCT04175444 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: VisuALL Field Analyzer
Description: Each participant will conduct a visual field test with the visuaALL headset.
Study NCT04175444 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Humphrey Field Analyzer
Description: Each participant will conduct a standard of care Humphrey Visual Field.
Study NCT03603548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envarsus
Description: Patients after liver transplantation initially treated with traditional Tacrolimus variant- Prograf, switched on day 10 after OLTx on prolonged released Tacrolimus variant in 1:1 ratio ( Advagraf vs. Envarsus)
Study NCT03603548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advagraf
Description: Patients after liver transplantation initially treated with traditional Tacrolimus variant- Prograf, switched on day 10 after OLTx on prolonged released Tacrolimus variant in 1:1 ratio ( Advagraf vs. Envarsus)
Study NCT03791710 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: autologous fat grafting
Description: regular liposuction procedure at which sufficient amount of fat is extracted from the patient and then the fat is processed then grafted underneath the burn wound
Study NCT03791710 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Cream
Description: serial dressing with topical agents e.g Silver Sulphadiazine
Study NCT03791710 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: split thickness skin grafting
Description: depridment and split thickness skin grafting
Study NCT03791710 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: split thickness skin grafting
Description: depridment and split thickness skin grafting
Study NCT04091659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Education
Description: Virtual Reality Education (Intervention): The experimental group of libraries will receive the virtual reality simulation, which is guided by the NLN Jeffries Simulation Theory, and lasts 9 minutes. The virtual reality education is based on scenes and dialogue conducted during the hybrid high-fidelity simulation, from a script developed using the existing hybrid simulation on opioid overdose intervention. This virtual reality education is an educational intervention.
Study NCT04091659 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Education
Description: Standard Educational (Control): The public health department's training includes printed handouts on how to administer naloxone and youtube videos on how to spot signs and symptoms of overdose and administer naloxone. Additionally, staff are on hand to provide one on one verbal educational trainings to local community members voluntarily seeking education.
Study NCT03400943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: 2 mg of Vilaprisan once daily up to 2 x 12 weeks
Study NCT03400943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo was administered to group B1 and B2.
Study NCT01830634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Theraband with strengthening and stretching exercise
Description: Using the theraband for strengthening and stretching the upper and lower extremity muscles.~All exercises were performed by using a Theraband in the following movements: shoulder elevating and abducting, horizontal and oblique direction, plantar flexion, dorsi-flexion, inversion and eversion of ankle, knee extension and hip abduction. The stretching exercises were focused on the hamstring muscle and heel cord. Each movement was held for 5 seconds. The participants were instructed to perform 5-10 repetitions of each movements twice per day.
Study NCT01162746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone and intravitreal ranibizumab
Description: Patients will receive intravitreal dexamethasone using a special drug delivery system and same day intravitreal ranibizumab.~Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual decrease or persistence of sub-/intraretinal fluid is detected in the examination. At month 3, 6, 9 and 12 further treatments with intravitreal dexamethasone in combination with intravitreal ranibizumab are given if leakage is detected in fluorescein or indocyanine green (FLA or ICG) angiography, in case of further vision decrease or persistence of sub-/intraretinal fluid in OCT.
Study NCT01283178 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo intensity-modulated image-guided adaptive radiotherapy
Study NCT01283178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT01283178 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: image-guided adaptive radiation therapy
Description: Undergo intensity-modulated image-guided adaptive radiotherapy
Study NCT01283178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3'-deoxy-3'-[18F]fluorothymidine
Description: Undergo FLT-PET scans for IMRT/IGART
Study NCT01162746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal ranibizumab
Description: Patients will receive intravitreal ranibizumab monotherapy (cohort 3). Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual deterioration or persistence of sub-/intraretinal fluid is detected in the examination
Study NCT00899041 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty (TKA)
Description: 28 subjects will receive the standard Sigma FB knee prosthesis. 28 subjects will receive the high flexion Sigma RP-F knee prosthesis.
Study NCT00769990 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: genistein
Description: Genistein will be taken orally once daily as 500 mg capsules throughout the study (60 days).
Study NCT00769990 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: A course of palliative external beam radiation therapy -performed within 8 weeks prior to start of the study.
Study NCT04293328 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: orthokeratology
Description: Nightly wear of orthokeratology lenses to correct vision in the daytime
Study NCT04293328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: orthokeratology
Description: Nightly wear of orthokeratology lenses to correct vision in the daytime
Study NCT04293328 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Menicon Progent A+B
Description: Menicon Progent A+B is a commercially available protein remover for rigid lenses. It has received FDA clearance and been launched in Hong Kong for over a decade. The product contains two separate sterile solutions, one with sodium hypochlorite and the other with potassium bromide. By mixing the two solutions in a special vial, it can clean and remove protein deposits on the lenses. Parents of subjects assigned to use weekly protein remover will be required to soak the cleansed lenses in the solution mixture for not more than 30 mins every week. All lenses must be rinsed thoroughly with saline and cleansed with daily cleaner again before daily disinfection.
Study NCT03596892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine was administered at 20mg/m2/day on days -14 and -10.
Study NCT03596892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
Study NCT03596892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
Study NCT03596892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Study NCT03596892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Study NCT01551108 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention: limited behavioral strategies
Description: Parents are given access to a website, formatted for a mobile phone. The website provides parents with a target steps/day goal for their child and parents are instructed to use their mobile phone to access the study website to record their child's step count each night. Parents are also sent monthly healthy nutrition tips via text message targeting the child in order to provide these families with potentially health promoting information.
Study NCT01283178 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography/computed tomography
Description: Undergo FDG/FLT-PET scans for IMRT/IGARTT
Study NCT01283178 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Undergo FDG-PET scans for IMRT/IGART
Study NCT03480646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-1205
Description: Administered orally
Study NCT02367183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GED-0301
Study NCT03480646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Administered orally
Study NCT03480646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone/Prednisone
Description: Administered orally
Study NCT03803449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50-200mg propofol
Description: participants in both groups are given standard regimen including 50-200mg propofol.
Study NCT03803449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50-200mg propofol
Description: participants in both groups are given standard regimen including 50-200mg propofol.
Study NCT03803449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50ug fentanyl
Description: participants in fentanyl group are given intervention regimen: 50ug fentanyl.
Study NCT03803449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 mg midazolam
Description: participants in both groups are given standard regimen including 1 mg midazolam.
Study NCT03803449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg midazolam
Description: participants in both groups are given standard regimen including 1 mg midazolam.
Study NCT02789189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nedaplatin and gemcitabine
Study NCT02776306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Box therapy
Description: In mirror box therapy the patient uses the reflection of their good arm to trick to brain into thinking that the effected arm is working.
Study NCT00419237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW685698X
Description: GW685698X will be available as dry white powder to be inhaled via DISKUS containing cellobiose octaacetate (COA) blended with lactose.
Study NCT00419237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X
Description: GW685698X will be available as dry white powder to be inhaled via DISKUS containing cellobiose octaacetate (COA) blended with lactose.
Study NCT00805038 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transplant navigator
Description: Navigator will provide help to patients in completing specific steps in transplant process.
Study NCT00805038 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Nephrologists and dialysis facilities will provide usual care regarding access to transplantation.
Study NCT00345514 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention Arm
Description: The arm emphasized individual provider behavior (interactive CME, feedback at the provider, clinic and program levels, expert modeling, academic detailing and opinion leaders)
Study NCT00345514 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Organizational Interventions Arm
Description: Leadership, team building, benchmarking at the clinic and program level